The CD Antigen Cancer Therapy Market Size is valued at USD 26.2 Bn in 2023 and is predicted to reach USD 41.8 Bn by 2031 at a 6.21% CAGR during the forecast period for 2024-2031.
CD antigen cancer therapy is a tailored treatment method that targets specific proteins on the surface of cancer cells. These proteins are called CD antigens. An increasing number of malignancies are being diagnosed on a global scale, which is driving the CD antigen cancer therapy market to search for more effective treatments. Biotechnology and immunotherapy have progressed to the point that new CD antigen-targeting medications have been developed.
CD antigen cancer therapy is being accelerated by an uptick in cancer cases, rising investments in cancer research initiatives from governments, private organizations, and pharmaceutical companies and favourable regulatory frameworks to develop novel therapies. These factors lead to better healthcare outcomes and individualized treatment options. However, the market expansion is hampered by the strict regulatory criteria of CD antigen cancer therapy, and creating therapy, researching, and developing strategies to target CD antigen cancer therapy is time-consuming and expensive.
Competitive Landscape
Some Major Key Players In the CD Antigen Cancer Therapy Market:
- Novartis AG
- Roche Holdings AG
- Bristol Myers Squibb Company
- Gilead Sciences Inc.
- Merck & Co. Inc.
- Johnson & Johnson
- Amgen Inc.
- AbbVie Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- Seattle Genetics Inc.
- Biogen Inc.
- Celgene Corporation
- Genmab A/S
- Immunomedics Inc.
- Others
Market Segmentation:
The CD antigen cancer therapy market is segmented based on the type of CD antigen targeted, therapy type, cancer type, and end-user. Based on the type of CD antigen targeted, the market is segmented into CD19, CD20, CD30, CD33, CD38, CD70, and others. By therapy type, the market is segmented into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, Bi-specific T-cell engagers (BiTEs), radioimmunotherapy, and immunotoxins. By cancer type, the market is segmented into leukemia, lymphoma, multiple myeloma, breast cancer, lung cancer, prostate cancer, and others. End-users segment the market into hospitals, specialty clinics, cancer treatment centres, and research institutes.
Based on the cancer type, the breast cancer segment accounts for a significant share of the CD antigen cancer therapy market
The breast cancer segment is expected to hold a significant share in the global CD antigen cancer therapy market in 2023 because of the widespread occurrence and high rates of breast cancer globally. Due to recent developments in targeted therapeutics, high-quality breast cancer medicines based on CD antigens have been developed. Additionally, by improving results and offering tailored therapy options for breast cancer patients, these medicines have been rapidly adopted due to significant investments in research and positive regulatory approvals.
Cancer treatment centre segment to witness growth at a rapid rate
The cancer treatment centres segment is expected to grow rapidly in the CD antigen cancer therapy market because cutting-edge, professional cancer therapies are in high demand to provide tailored medicines, such as those based on CD antigens. These centres have the most recent technology and skilled professionals. There is a growing need for specialized treatment centres due to the increasing incidence of cancer and better patient outcomes made possible by these medicines. Another factor helping to fuel the rise of cancer treatment facilities worldwide is the growing funding and public interest in oncology research.
The North American CD antigen cancer therapy Market holds a significant revenue share in the region.
The North American CD antigen cancer therapy market is expected to register the highest market share in revenue in the near future. It can be attributed to the developed healthcare system, substantial investments in R&D, high cancer rates, rapid implementation of new treatments, state-of-the-art research facilities, and partnerships between universities and biotech firms to speed up the development of CD antigen cancer therapy. In addition, the Asia Pacific is anticipated to grow rapidly in the global CD antigen cancer therapy market because there has been a dramatic increase in cancer rates, healthcare costs, the availability of cutting-edge treatments, and funding for healthcare infrastructure and research, which is the expansion of the region's growth.
Recent Developments:
- In March 2024, Bristol Myers Squibb received FDA approval for its CAR-T cell therapy; Breyanzi, a CD19-directed CART therapy, for adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma who have received at least two prior lines of therapy.
- In 2023, Gilead Sciences, Inc. received FDA approval for its Trodelvy, Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer to treat inoperable locally advanced or metastatic breast cancer in adults.
CD Antigen Cancer Therapy Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 26.2 Bn |
|
Revenue Forecast In 2031 |
USD 41.8 Bn |
|
Growth Rate CAGR |
CAGR of 6.21 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By CD Antigen Targeted, Therapy Type, Cancer Type, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis AG, Roche Holdings AG, Bristol Myers Squibb Company, Gilead Sciences Inc., Merck & Co. Inc., Johnson & Johnson, Amgen Inc., AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Seattle Genetics Inc., Biogen Inc., Celgene Corporation, Genmab A/S, Immunomedics Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
